Target intelligence / Profile preview

HIV-1 Pol polyprotein (HIV-1 Pol)

Target
HIV-1 Pol
Molecular classification
Enzyme, Aspartic protease, RNA-directed DNA polymerase, DNA-directed DNA polymerase, Ribonuclease H, Integrase
01

Overview

HIV-1 Pol is a multifunctional polyprotein essential for the replication and maturation of the Human Immunodeficiency Virus type 1 (UniProt P03366). It is synthesized as a Gag-Pol precursor (p160) through a ribosomal frameshift and is subsequently cleaved by the viral protease into three distinct enzymes: protease (PR), reverse transcriptase (RT), and integrase (IN). The protease is responsible for processing viral polyproteins into functional units, reverse transcriptase converts the viral RNA genome into double-stranded DNA, and integrase facilitates the insertion of this DNA into the host cell genome (NIH: HIV Life Cycle). As a central component of the viral life cycle, Pol is the primary target for most antiretroviral therapies (ART), including protease inhibitors, reverse transcriptase inhibitors, and integrase inhibitors (FDA: Antiretroviral Drugs). In the context of HIV-MAG DNA, the Pol sequence is utilized as a vaccine antigen, often modified to eliminate enzymatic activity while retaining immunogenicity to elicit T-cell responses against conserved viral epitopes (: NCT00069511). This multi-antigen approach aims to provide broad protection by targeting multiple stages of the viral life cycle and reducing the likelihood of immune escape.

Other names
Pol proteinHIV-1 polymeraseP160 Gag-Pol precursorReverse transcriptase-protease-integrase polyproteinp66/p51 Reverse transcriptasep32 Integrasep11 Protease
02

Mechanism of action

Inhibition of viral enzymes (protease, reverse transcriptase, or integrase) to prevent viral replication, genome integration, and maturation.

03

Biological functions

Viral replicationViral maturationReverse transcriptionIntegrationProteolysis
04

Disease associations

InfectionAcquired Immunodeficiency Syndrome (AIDS)
05

Safety considerations

Development of multi-drug resistanceMitochondrial toxicityLipodystrophy and metabolic syndromeHepatotoxicityRenal impairment (e.g., Fanconi syndrome with Tenofovir)Immune Reconstitution Inflammatory Syndrome (IRIS)
06

Interacting drugs

10 more in the full profile.

07

Biomarkers

HIV-1 RNA viral loadCD4+ T-lymphocyte countPol gene resistance mutations (e.g., K103N, M184V, Q148H)HLA-B*5701 (for Abacavir sensitivity)

Source types: Peer-reviewed publication · Trial registry. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on HIV-1 Pol polyprotein (HIV-1 Pol).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIV-1 Pol polyprotein (HIV-1 Pol).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call